title: Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group.
abstract: The study aimed to assess prognostic significance of del(13q14), del(17p13), t(4;14)(p16;q32), and amp(1q21) in newly diagnosed myeloma patients treated mostly with thalidomide-based therapies. All genetic abnormalities except del(13q14) were independent prognostic factors associated with shortened progression-free survival (PFS) and overall survival (OS). Patients with no abnormalities, one abnormality, and ≥2 abnormalities had a median PFS of 41.8, 17.0, and 10.0 months, respectively; a median OS was not reached, 48.0 and 23.3 months, respectively. According to the presence of amp(1q21), t(4;14)(p16;q32), and del(17p13) and the International Staging System (ISS), we stratified patients into low-risk, intermediate-risk and high-risk groups. A median PFS was 52.9, 25.6, and 10.0 months, respectively; a median OS was not reached, 64.0 and 25.0 months, respectively. In conclusion, our study confirmed the prognostic value of cytogenetic changes and showed that prognostic models based on ISS and cytogenetic studies should include not only del(17p13) and t(4;14)(p16;q32), but also amp(1q21).
authors.affiliation: a Department of Hematology , St. John's Cancer Center , Lublin , Poland.|b Department of Experimental Hematooncology , Medical University of Lublin , Lublin , Poland.
authors.forename: Norbert
authors.initials: N
authors.lastname: Grzasko
authors.affiliation: c University Hospital Ostrava and Faculty of Medicine, University of Ostrava , Ostrava , Czech Republic.
authors.forename: Roman
authors.initials: R
authors.lastname: Hajek
authors.affiliation: b Department of Experimental Hematooncology , Medical University of Lublin , Lublin , Poland.
authors.forename: Marek
authors.initials: M
authors.lastname: Hus
authors.affiliation: b Department of Experimental Hematooncology , Medical University of Lublin , Lublin , Poland.
authors.forename: Sylwia
authors.initials: S
authors.lastname: Chocholska
authors.affiliation: a Department of Hematology , St. John's Cancer Center , Lublin , Poland.
authors.forename: Marta
authors.initials: M
authors.lastname: Morawska
authors.affiliation: a Department of Hematology , St. John's Cancer Center , Lublin , Poland.|b Department of Experimental Hematooncology , Medical University of Lublin , Lublin , Poland.
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Giannopoulos
authors.affiliation: a Department of Hematology , St. John's Cancer Center , Lublin , Poland.|d Department of Ergonomics, Faculty of Management, Lublin University of Technology , Lublin , Poland.
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Czarnocki
authors.affiliation: e Department of Lymphoproliferative Diseases , Maria Sklodowska-Curie Memorial Institute and Oncology Centre , Warsaw , Poland.
authors.forename: Agnieszka
authors.initials: A
authors.lastname: Druzd-Sitek
authors.affiliation: e Department of Lymphoproliferative Diseases , Maria Sklodowska-Curie Memorial Institute and Oncology Centre , Warsaw , Poland.
authors.forename: Barbara
authors.initials: B
authors.lastname: Pienkowska-Grela
authors.affiliation: e Department of Lymphoproliferative Diseases , Maria Sklodowska-Curie Memorial Institute and Oncology Centre , Warsaw , Poland.
authors.forename: Jolanta
authors.initials: J
authors.lastname: Rygier
authors.affiliation: f Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation , Wroclaw Medical University , Wroclaw , Poland.
authors.forename: Lidia
authors.initials: L
authors.lastname: Usnarska-Zubkiewicz
authors.affiliation: g Department of Hematology and Bone Marrow Transplantation Poznan , Poznan University of Medical Sciences , Poland.
authors.forename: Dominik
authors.initials: D
authors.lastname: Dytfeld
authors.affiliation: g Department of Hematology and Bone Marrow Transplantation Poznan , Poznan University of Medical Sciences , Poland.
authors.forename: Tadeusz
authors.initials: T
authors.lastname: Kubicki
authors.affiliation: h Department of Hematology , Jagiellonian University Medical College , Cracow , Poland.
authors.forename: Artur
authors.initials: A
authors.lastname: Jurczyszyn
authors.affiliation: i Department of Biochemical Diagnostics , Medical University of Lublin , Lublin , Poland.
authors.forename: Maciej
authors.initials: M
authors.lastname: Korpysz
authors.affiliation: j Polish Myeloma Study Group , Lublin , Poland.
authors.forename: Anna
authors.initials: A
authors.lastname: Dmoszynska
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D002872:Chromosome Deletion; D058674:Chromosome Duplication; D002878:Chromosomes, Human, Pair 1; D002883:Chromosomes, Human, Pair 14; D002886:Chromosomes, Human, Pair 17; D002894:Chromosomes, Human, Pair 4; D005260:Female; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D015994:Incidence; D008297:Male; D009101:Multiple Myeloma / Q000453:epidemiology / Q000235:genetics* / Q000401:mortality; D011044:Poland / Q000453:epidemiology; D011379:Prognosis; D012189:Retrospective Studies; D016019:Survival Analysis; D014178:Translocation, Genetic
keywords: Multiple myeloma; cytogenetic abnormalities; prognosis; thalidomide